James Campbell
Follow
Get notifications in MyBN when activity occurs.
James Campbell
Chief Executive, Managing Director / Patrys
Most Notable Role
Dr James Campbell has extensive experience as a scientist and commercial executive within the medical sector.
He was chief financial officer and chief operating officer of Chemgenex which was acquired by Cephalon for $230million in 2011. At ChemGenex, his responsibilities ranged from intellectual property management to licensing and business development. Dr Campbell had also guided the creation of Invion Limited as an executive director, and assisted private biotechnology companies in New Zealand and the US with capital raising and partnering negotiations.
He was chief financial officer and chief operating officer of Chemgenex which was acquired by Cephalon for $230million in 2011. At ChemGenex, his responsibilities ranged from intellectual property management to licensing and business development. Dr Campbell had also guided the creation of Invion Limited as an executive director, and assisted private biotechnology companies in New Zealand and the US with capital raising and partnering negotiations.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| th | TTA Holdings | -84% | -29% |
| 1408th | Prescient Therapeutics | -46% | -4% |
| 1552nd | Papyrus Australia | -55% | 7% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 926th |  | Prescient Therapeutics | $2.4m |
| 1115th | | Lifespot Health | $107k |
| 1117th | | TTA Holdings | $107k |
| 1120th | | County International | $98k |
| 1121st | | Papyrus Australia | $98k |
1328 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Chief Executive, Managing Director, Patrys | 03 Nov 2020 |
